Franco Maggiolo

Summary

Publications

  1. ncbi request reprint Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 8:339-46. 2003
  2. doi request reprint Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients
    Franco Maggiolo
    Unit of Antiviral Therapy, Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 15:51-9. 2010
  3. pmc One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects
    Monica Airoldi
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo
    Patient Prefer Adherence 4:115-25. 2010
  4. pmc Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
    Davide Motta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Res Ther 9:18. 2012
  5. doi request reprint Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure
    Franco Maggiolo
    Division of Infectious Diseases, pedali Riuniti, Bergamo, Italy
    J Acquir Immune Defic Syndr 60:473-82. 2012
  6. ncbi request reprint Switch strategies in patients on effective HAART
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Largo Barozzi 1, Bergamo 24128, Italy
    J Antimicrob Chemother 55:821-3. 2005
  7. ncbi request reprint Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    J Antimicrob Chemother 59:569-72. 2007
  8. ncbi request reprint The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 11:923-9. 2006
  9. ncbi request reprint Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    HIV Clin Trials 8:9-18. 2007
  10. ncbi request reprint Efavirenz
    Franco Maggiolo
    Unit of Antiviral Therapy, Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Expert Opin Pharmacother 8:1137-45. 2007

Collaborators

Detail Information

Publications46

  1. ncbi request reprint Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 8:339-46. 2003
    ..Complex antiretroviral regimens require optimal adherence to maintain long-lasting effectiveness. Simpler regimens, possibly with easy schedule and low pill burden, are needed for the long-term treatment of HIV infection...
  2. doi request reprint Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients
    Franco Maggiolo
    Unit of Antiviral Therapy, Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 15:51-9. 2010
    ....
  3. pmc One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects
    Monica Airoldi
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo
    Patient Prefer Adherence 4:115-25. 2010
    ..The aim of the ADONE (ADherence to ONE pill) study was to verify the effect of a reduced number of pills on adherence and quality of life (QoL) in HIV-infected patients on highly active antiretroviral therapy (HAART)...
  4. pmc Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
    Davide Motta
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Res Ther 9:18. 2012
    ..abstract:..
  5. doi request reprint Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure
    Franco Maggiolo
    Division of Infectious Diseases, pedali Riuniti, Bergamo, Italy
    J Acquir Immune Defic Syndr 60:473-82. 2012
    ..Low-level viremia (LLV) is measurable, with enhanced assays, in many subjects with HIV RNA levels <50 copies per milliliter. The clinical consequences of LLV are unknown...
  6. ncbi request reprint Switch strategies in patients on effective HAART
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Largo Barozzi 1, Bergamo 24128, Italy
    J Antimicrob Chemother 55:821-3. 2005
    ..NRTI switches may also be beneficial in reducing the risk of lactate level elevation, mitochondrial toxicity, insufficient immunological response to HAART and of selecting class-inducing resistance mutations...
  7. ncbi request reprint Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    J Antimicrob Chemother 59:569-72. 2007
    ..To evaluate the frequency of and predictive factors for nevirapine-based highly active antiretroviral therapy (HAART) discontinuation...
  8. ncbi request reprint The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 11:923-9. 2006
    ..One of the more vigorous debates in the field of highly active antiretroviral therapy (HAART) is how to start it and what the optimal drug sequence is...
  9. ncbi request reprint Resistance costs and future drug options of antiretroviral therapies: analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    HIV Clin Trials 8:9-18. 2007
    ..To investigate future drug options (FDOs), resistance cost (RCVF), and virologic response to genotypic-driven rescue highly active antiretroviral therapy (HAART), according to type of therapy...
  10. ncbi request reprint Efavirenz
    Franco Maggiolo
    Unit of Antiviral Therapy, Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Expert Opin Pharmacother 8:1137-45. 2007
    ..As non-nucleoside reverse transcriptase inhibitors have a distinctive adverse-event profile, protease inhibitor-sparing regimens may reduce the risk of metabolic complications, insulin resistance and peripheral fat redistribution...
  11. ncbi request reprint Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    HIV Clin Trials 8:282-92. 2007
    ..The effect of adherence on the risk of virologic failure and mutations selection was verified in a prospective study...
  12. doi request reprint CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART
    Franco Maggiolo
    Division of Infectious Diseases, Unit of Antiviral Therapy, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    AIDS 23:799-807. 2009
    ..To compare continuous HAART with a CD4 cell-driven scheduled treatment interruption (STI) strategy...
  13. pmc Efavirenz: a decade of clinical experience in the treatment of HIV
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Largo Barozzi 1, Bergamo, Italy
    J Antimicrob Chemother 64:910-28. 2009
    ..Recent data have confirmed that efavirenz is a cost-effective option for first-line HAART. In light of these features, efavirenz retains a key role in HIV treatment strategies and is the first-line agent recommended in some guidelines...
  14. ncbi request reprint Quadruple-drug induction HAART in advanced HIV infection
    Franco Maggiolo
    Division of Infectious Diseases, Antiviral Therapy Unit, Ospedali Riuniti di Bergamo, Italy
    HIV Clin Trials 6:1-4. 2005
    ..Despite this, we observed a significant (p </= .001) increment of CD4. The theoretical advantages of induction-maintenance strategies are tempered by an increased risk of adverse experiences...
  15. ncbi request reprint Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 8:121-6. 2003
    ..Further studies should clarify whether this is true for other drugs of the nucleoside analogues class...
  16. ncbi request reprint Once-a-day HAART: dream or reality?
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    HIV Clin Trials 4:193-201. 2003
    ..The range of once-daily options is expanding rapidly, and the patients' request for easier therapies that are respectful of their lifestyle could be fulfilled...
  17. ncbi request reprint Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy
    HIV Clin Trials 3:371-8. 2002
    ..Many factors may influence compliance to such demanding regimens, and their identification may help in the design of strategies to enhance adherence...
  18. ncbi request reprint Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz
    F Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 6:249-53. 2001
    ..These encouraging pilot results need to be confirmed in a comparative clinical trial...
  19. ncbi request reprint In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus
    F Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    J Chemother 12:195-8. 2000
    ....
  20. ncbi request reprint Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, 24128 Bergamo, Italy
    Clin Infect Dis 37:41-9. 2003
    ..001), with no significant difference between groups. This switching strategy maintains optimal levels of virological suppression and may improve lipid profiles in most patients...
  21. ncbi request reprint Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors
    Franco Maggiolo
    Division of Infectious Diseases, Unit of Antiviral Therapy, Ospedali Riuniti, Bergamo, Italy
    Clin Infect Dis 40:158-63. 2005
    ..This prospective study verified the effect of adherence on the risk of virologic failure...
  22. ncbi request reprint Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial
    Franco Maggiolo
    Division of Infectious Diseases and the Microbiology and Virology Laboratory, Ospedali Riuniti, Bergamo, Italy
    AIDS 18:439-46. 2004
    ..The primary end-point was the proportion of subjects maintaining CD4 cell count > 400 x 10 cells/l. Secondary end-points were to identify the dynamic and predictive variables of CD4 cell loss...
  23. ncbi request reprint Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer
    Diego Ripamonti
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    AIDS 21:2409-15. 2007
    ..Pregnancy can alter drug kinetics. We assessed the pharmacokinetics of atazanavir/ritonavir (300/100 mg a day) during pregnancy...
  24. ncbi request reprint Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance
    Franco Maggiolo
    Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo, Italy, Unità di Terapia Antivirale, Ospedali Riuniti, Bergamo, Italy
    J Int Assoc Physicians AIDS Care (Chic) 6:87-93. 2007
    ..Their use may help clinicians in interpreting mutational patterns and in making therapeutic choices...
  25. ncbi request reprint Factors associated with the failure of HIV-positive persons to return for scheduled medical visits
    Claudio Arici
    Unita Operativa di Malattie Infettive, Ospedali Riuniti di Bergamo, Largo Barozzi, Bergamo, Italy
    HIV Clin Trials 3:52-7. 2002
    ..To assess in an HIV-positive cohort the cumulative probability of failing to return for scheduled medical visits and to address the factors associated with follow-up discontinuation...
  26. ncbi request reprint Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients
    Diego Ripamonti
    Antiviral Therapy Unit, Infectious Diseases Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    AIDS 18:334-7. 2004
    ..Predictors of modification of the regimen were hepatitis C seropositivity, liver cirrhosis, higher baseline viral load, sex (women had a lower risk) and calendar year (lower risk staring in 2000)...
  27. ncbi request reprint Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection
    Dario Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Chromatogr Sci 46:485-9. 2008
    ....
  28. ncbi request reprint Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection
    Diego Ripamonti
    Malattie Infettive, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy
    Curr Opin Investig Drugs 9:899-912. 2008
    ..A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010...
  29. doi request reprint Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection
    Sharon L Walmsley
    From the University Health Network, Toronto S L W Hospital Clinico Universitario, Santiago de Compostela A A, and Hospital General de Elche and Universidad Miguel Hernández, Alicante F G both in Spain Centre Hospitalier Universitaire Saint Pierre, Brussels N C Dr Victor Babes Infectious and Tropical Diseases Hospital, Bucharest, Romania D D Medizinisches Versorgungszentrum Karlsplatz HIV Research and Clinical Care Center, Munich, Germany A E Centre Hospitalier Régional d Orléans, Orleans, France L H Antiviral Therapy Unit, Ospedali Riuniti, Bergamo, Italy F M University of Nebraska Medical Center, Omaha U S GlaxoSmithKline, Stockley Park, United Kingdom C G and GlaxoSmithKline, Research Triangle Park, NC K P, B W, S M, G N
    N Engl J Med 369:1807-18. 2013
    ..Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen...
  30. doi request reprint Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008
    Annapaola Callegaro
    Microbiology and Virology, Ospedali Riuniti di Bergamo, Italy
    Infect Genet Evol 11:624-32. 2011
    ....
  31. pmc Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
    Claudia Bernardini
    Division of Infectious Diseases and Unit of Antiviral Therapy, AO Papa Giovanni XXIII, Bergamo, Italy
    Patient Prefer Adherence 7:531-42. 2013
    ..Furthermore, the use of this STR in the therapeutic switch, like in the SPIRIT study, can result in another valuable option by which to reduce AEs and improve patients' quality of life. ..
  32. ncbi request reprint Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C
    Eliseo Minola
    Infectious Diseases Unit, Ospedali Riuniti, Bergamo, Italy
    Blood 99:4588-91. 2002
    ..Our findings suggest that an aggressive therapeutic approach should be adopted in patients infected by HCV at an older age to prevent the progression to end-stage liver disease...
  33. ncbi request reprint Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients
    Mario Clerici
    Cattedra di Immunologia, Universita degli Studi di Milano, DISP LITA Vialba, Milano, Italy
    AIDS 16:1767-73. 2002
    ..Control of HIV replication can be observed in highly active antiretroviral therapy (HAART)-treated and, occasionally, in HAART-naive patients. The immunological correlates of these situations were examined in a longitudinal study...
  34. ncbi request reprint HIV-1 and hepatitis B virus: time for a re-think?
    Diego Ripamonti
    Lancet 363:1400. 2004
  35. ncbi request reprint Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens
    Diego Ripamonti
    AIDS 16:130-1. 2002
  36. ncbi request reprint A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients
    Massimo Puoti
    Clinica di Malattie Infettive e Tropicali, AO Spedali Civili di Brescia, Universita di Brescia, Brescia, Italy
    J Hepatol 41:312-8. 2004
    ..To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety of standard anti-hepatitis C virus (HCV) treatment in HIV-infected patients...
  37. ncbi request reprint Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses
    Franco Maggiolo
    AIDS 16:298-9. 2002
  38. ncbi request reprint Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    J Antimicrob Chemother 56:190-5. 2005
    ....
  39. ncbi request reprint The Trivacan study
    Franco Maggiolo
    Lancet 368:915; author reply 916. 2006
  40. ncbi request reprint CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load
    Carlo Torti
    Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    J Antimicrob Chemother 59:1141-7. 2007
    ..We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination...
  41. ncbi request reprint Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation
    Andrea Antinori
    National Institute for Infectious Diseases L Spallanzani IRCCS, Roma, Italy
    Antivir Ther 12:1175-83. 2007
    ..The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined...
  42. ncbi request reprint Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman
    Diego Ripamonti
    AIDS 21:1059-60. 2007
  43. ncbi request reprint Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART
    Renato Maserati
    HIV AIDS Outpatient Clinic, Infectious Disease Dept, at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Curr HIV Res 5:337-43. 2007
    ..Cyclic structured treatment interruptions may have a favorable, although limited, impact on plasma total cholesterol levels in HIV-infected subjects. No modifications of anthropometric and quality of life values were noted...
  44. ncbi request reprint Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3
    Giuseppe Lapadula
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    Antivir Ther 12:941-7. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events (ADE) or death among patients who started HAART with CD4+ T-cell counts > or =200 cells/mm3 have rarely been assessed simultaneously...
  45. ncbi request reprint Predictors of AIDS-defining events among advanced naïve patients after HAART
    Carlo Torti
    Institute for Infectious and Tropical Diseases, University of Brescia, Italy
    HIV Clin Trials 8:112-20. 2007
    ..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously...
  46. ncbi request reprint Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions
    Andrea Foli
    RIGHT at IRCCS Policlinico S Matteo, Pavia, Italy
    Antivir Ther 9:123-32. 2004
    ..However, an appropriate choice of drugs and properly scheduled structured treatment interruptions (STIs) may limit VL rebound, maintain CD4 counts and minimize resistance...